The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessing the impact of scalp cooling in patients receiving trastuzumab deruxtecan for metastatic breast cancer.
 
Elahe Salehi
Research Funding - AstraZeneca (Inst); Paxman (Inst)
 
Xiangying Chu
No Relationships to Disclose
 
Erica Mayer
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis
 
Sean Singer
No Relationships to Disclose
 
Michael Stalteri
Employment - Dana-Farber Cancer Institute
 
Tianyu Li
No Relationships to Disclose
 
Kate Dibble
Stock and Other Ownership Interests - AstraZeneca (I); Biointech (I); Moderna Therapeutics (I); Sanofi (I); Sanofi (I)
 
Natalie Sinclair
No Relationships to Disclose
 
Meredith Faggen
No Relationships to Disclose
 
Jeanna Walsh
Stock and Other Ownership Interests - Pfizer
 
Sarah Sammons
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Foundation Medicine; Incyclix Bio; Loxo/Lilly; Novartis; Pfizer; Relay Therapeutics; Sermonix Pharmaceuticals
Research Funding - AstraZeneca/MedImmune (Inst); Lilly (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)
 
Kerry Sendrick
No Relationships to Disclose
 
Sara Hanna
No Relationships to Disclose
 
Arash Mostaghimi
Honoraria - Abbvie; ASLAN Pharmaceuticals; Boehringer Ingelheim; Equillium; Hims; Legacy Healthcare Services; Lilly; Pfizer; Sun Pharma
Research Funding - Lilly (Inst); Lilly (Inst); Lilly (Inst); Sun Pharma (Inst)
 
Nabihah Tayob
No Relationships to Disclose
 
Nicole LeBoeuf
Consulting or Advisory Role - Fortress Biotech; Silverback Therapeutics; SynOX
 
Sara Tolaney
Consulting or Advisory Role - AADi; Ambrx; Artios Biopharmaceuticals; Arvinas; AstraZeneca; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Blueprint Medicines; Bristol-Myers Squibb; Circle Pharma; Cullinan Oncology; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Summit Therapeutics; Systimmune; Tango Therapeutics; Zentalis; Zuellig Pharma; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Arvinas; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Sanofi
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences